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Abstract 
We investigated the incidences of febrile neutropenia (FN) and related complications in 
elderly (≥65 years) breast cancer patients receiving chemotherapy supported by pegfilgrastim 
primary prophylaxis (PP; n=150) or current practice (CP) neutropenia management (n=104) 
in a subanalysis of NeuCuP (Neulasta vs. Current Practice Neutropenia Management). Studies 
involving regimens with moderately-high to high (≥15%) FN risk were identified by literature 
review, and individual patient data were integrated for analysis. FN incidence was 6% (95% 
CI: 2%, 10%) in the PP group and 24% (95% CI: 16%, 32%) in the CP group. In cycle 1, 
incidences were 3% and 15%, respectively. FN-related hospitalisation incidence was 5% (PP 
group) and 15% (CP group), while dose reductions (≥15%) occurred in 15% and 29% of 
patients. Pegfilgrastim provided effective PP in elderly patients, a population who may be 
vulnerable to chemotherapy-related FN and for whom current practice may not provide 
adequate protection. 
 
Keywords: Breast cancer; Chemotherapy; Elderly; Febrile neutropenia; G-CSF; 
Pegfilgrastim; Primary prophylaxis 
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1. Introduction 
In adult cancer patients receiving chemotherapy, febrile neutropenia (FN) is associated with 
considerable morbidity and in-hospital mortality of up to 10%, the risk of which increases 
substantially in the presence of comorbidities [1,2]. Furthermore, FN and severe neutropenia 
are common causes of dose delays and reductions in patients receiving chemotherapy for 
breast cancer. While the relative dose intensity (RDI) achieved may reflect underlying patient 
factors such as age and co-morbidity, data from studies in the adjuvant setting suggest that 
failure to receive planned dose contributes to poorer survival [3–5]. Ensuring optimal RDI is 
also a consideration in patients with metastatic disease when the aim of treatment is to 
prolong life [6,7]. Recent evidence-based guidelines issued by the European Organisation for 
Research and Treatment of Cancer (EORTC) [6], the American Society for Clinical Oncology 
(ASCO), [8] the National Comprehensive Cancer Network [9] and the European Society of 
Medical Oncology (ESMO) [10] recommend primary prophylaxis (PP) with granulocyte 
colony-stimulating factor (G-CSF) for all cancer patients at ≥20% overall risk of FN during 
chemotherapy. Guidelines such as these are becoming widely accepted in clinical practice 
[11], and their introduction has meant an increase in the number of patients who qualify for 
primary prophylaxis, increased recognition of the patient factors that contribute to FN, and the 
increasing use of dose-dense chemotherapy regimens [12]. 
 
One patient group at particular risk of FN is the elderly.  Older patients with breast cancer 
may be substantially more likely to experience haematological toxicity compared with 
younger individuals [13–15], but they derive the same proportional benefits from more 
intensive chemotherapy [16]. The EORTC [17] and German oncology association [18] have 
issued guidelines relating specifically to the use of G-CSF in elderly patients, noting that G-
CSF can reduce the incidence of chemotherapy-induced neutropenia in this population. It is 
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therefore recommended that older patients are given optimal chemotherapy, with appropriate 
growth factor support, to provide the best chance of cure/remission or, in those with more 
advanced cancer, effective prolongation of life [19,20]. 
 
Recently, data from an integrated analysis (NeuCuP [Neulasta vs Current Practice 
Neutropenia Management]) have shown that PP with pegfilgrastim provides superior 
protection against FN compared with current practice (CP) neutropenia management in breast 
cancer patients receiving chemotherapy with a moderately high to high risk of FN [21]. CP 
neutropenia management was defined as no G-CSF, or daily filgrastim and/or pegfilgrastim in 
any cycle. Overall, the odds for experiencing FN were significantly lower with PP 
pegfilgrastim than with CP neutropenia management over all cycles (P < 0.0001) and in cycle 
1 (P < 0.0001). Here, we assess the incidence of FN and related complications in the 
subgroup of elderly breast cancer patients.  
 
2. Methods 
2.1 Study design 
Full details of the NeuCuP analysis have been published previously [21]. Commonly used 
breast cancer chemotherapy regimens with moderately high (15–19%) or high (≥20%) FN 
risk were identified by Medline literature search using search terms including taxoids, 
(pegylated) doxorubicin, adriamycin, epirubicin, docetaxel, paclitaxel, cyclophosphamide, 
methotrexate and fluorouracil. When combined with the terms febrile neutropenia, 
neutropenia, leucopenia and infection, the Medline search produced 513 relevant articles. A 
review of data from a retrospective study by the Impact of Neutropenia in Chemotherapy 
European (INC-EU) study group  [22] provided further information on the FN risk associated 
with different regimens. Based on the literature review, several relevant chemotherapy 
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regimens were identified: doxorubicin (A) 50–60 mg/m2 or epirubicin (E) 75–100 mg/m2 + 
paclitaxel (T) 175–250 mg/m2, A(E) + docetaxel (Doc) 75–100 mg/m2, DocA(E) + 
cyclophosphamide (C), Doc monotherapy 100 mg/m2, A(E)C-Doc, A(E) + carboplatin (Cb) 
AUC 4–6, gemcitabine 750–1200 mg/m2 + A 30–60 mg/m2 (E 50–150 mg/m2)T, and 
vinorelbine 20–35 mg/m2 + Cb. As vinorelbine + Cb  and A(E) + Cb are not in common use, 
they were not included in the next stage of the analysis. 
 
For the integrated analysis, we identified 19 eligible Phase II–IV clinical trials and 
observational studies (conducted between 1998 and 2005) from the original literature review 
and supplementary searches of the clinical trial database at Amgen (including investigator-led 
studies funded [in part] by Amgen) and abstracts from the ASCO annual meeting (2000–
2005). All studies were required to involve the chemotherapy regimens noted above, with 
either PP pegfilgrastim (i.e. protocol-driven PP pegfilgrastim primary prophylaxis from cycle 
1) or CP neutropenia management. CP neutropenia management was defined as any approach 
in current use, including daily G-CSF in any cycle, pegfilgrastim in any cycle or no G-CSF 
use. Study arms in which G-CSF prophylaxis was mandatory were not eligible for inclusion 
in the CP group. The critical factor for inclusion of a study in the final analysis was ready 
access to data (including FN incidence) at the individual patient level. Eight studies were 
excluded due to lack of data access (details of these studies are given in the primary 
publication [21]). Consequently, 11 studies were included in the integrated analysis (Table 1).  
 
Descriptive summaries of demographic and disease characteristics were prepared for the 
individual studies and for the integrated populations of the PP pegfilgrastim and CP 
neutropenia management groups. G-CSF use was characterized by cycle in the PP 
pegfilgrastim and CP neutropenia management groups in terms of type of G-CSF received 
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and number of days of daily G-CSF used. The characteristics of patient populations from 
individual studies within the PP pegfilgrastim and CP neutropenia management groups were 
compared, with the conclusion that there was sufficient homogeneity to justify their 
integration. Integrated patient and treatment data from the PP pegfilgrastim and CP 
neutropenia management groups were then compared at the descriptive level. This analysis 
focuses on the subgroup of patients aged ≥65 years (Table 1). 
 
2.2 Outcome measures 
The primary outcome measure was the incidence of FN over all cycles. Secondary outcome 
measures reported here include the incidence of FN in cycle 1, incidence of FN-related 
hospitalisation over all cycles and in cycle 1, incidence of dose delays >3 days and >7 days in 
one or more cycles, incidence of dose reductions ≥10% and ≥15% in one or more cycles, and 
haematological toxicity.  
 
2.3 Statistical analysis 
Descriptive statistics were generated for the integrated data from the subgroup of patients 
aged ≥65 years. All outcome measures were binary in nature. Ninety-five percent confidence 
intervals (95% CI) were calculated where appropriate. 
 
3. Results 
3.1 Patient disposition 
Of 2282 patients included in the NeuCuP analysis, 285 patients were aged ≥65 years (PP 
pegfilgrastim, n = 181; CP, n = 104). In the PP pegfilgrastim group, 31 patients did not 
receive pegfilgrastim ‘per protocol’ from cycle 1, and were excluded from the final analysis. 
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Of the 150 remaining patients in the PP pegfilgrastim group, 109 (73%) completed all 
planned cycles of chemotherapy, while 78/104 patients (75%) in the CP group completed all 
planned cycles.  
 
3.2 Patient characteristics and chemotherapy 
Baseline characteristics were generally similar between the PP pegfilgrastim and CP groups 
(Table 2). Doc monotherapy was the most common regimen in the PP pegfilgrastim and CP 
groups, followed by DocAC and ADoc. Most regimens were prescribed for a similar 
proportion of patients in the PP pegfilgrastim and CP groups, although ADoc was more 
frequent in patients receiving PP pegfilgrastim (Table 2). 
 
3.3 G-CSF use 
In the PP pegfilgrastim group, all patients received pegfilgrastim in all cycles except cycle 2, 
in which one patient did not receive pegfilgrastim. No patient in the PP pegfilgrastim group 
received daily G-CSF. In cycle 1, 73% of patients in the CP group received no G-CSF, as did 
62% in cycle 6 (Figure 1). Of patients in the CP group who received daily G-CSF, where 
number of doses was specified, five or seven doses per cycle was most common.  
 
3.4 FN and related events 
During chemotherapy, the incidence of FN was substantially lower with PP pegfilgrastim 
(6%; 95% CI: 2%, 10%) than with CP neutropenia management (24%; 95% CI: 16%, 32%), 
particularly in cycle 1 (Figure 2). The lower incidence of FN in the PP pegfilgrastim group 
was accompanied by a lower incidence of FN-related hospitalisation in all cycles and in cycle 
1 (Figure 3). 
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The incidence of dose delays >3 days was numerically lower in patients receiving PP 
pegfilgrastim compared with CP neutropenia management (Figure 4), but confidence intervals 
overlapped considerably. The incidences of dose reductions of ≥10% and ≥15% in the PP 
pegfilgrastim group were approximately half those in the CP neutropenia group (Figure 5).  
 
3.5 Haematological toxicities 
Haematological toxicities (neutropenia, leukopenia, anaemia and thrombocytopenia) 
occurring during chemotherapy are shown in Table 3. Overall, National Cancer Institute 
Common Toxicity Criteria (NCI CTC) grade 3–4 neutropenia and leukopenia were more 
common in patients receiving CP neutropenia management than in those receiving PP 
pegfilgrastim. 
 
4. Discussion 
In this descriptive subgroup analysis involving 254 elderly patients receiving chemotherapy 
with a moderately high to high FN risk, PP pegfilgrastim resulted in a lower overall incidence 
of FN and FN-related hospitalisations compared with CP neutropenia management. 
Furthermore, the incidence of FN was reduced in cycle 1 (3% with PP pegfilgrastim and 15% 
with CP neutropenia management). This is particularly noteworthy, as it has previously been 
shown that the incidence of FN is higher in cycle 1 than in any other cycle [23,24]. The 
incidence of dose reductions in elderly patients receiving PP pegfilgrastim was approximately 
half that observed in patients receiving CP neutropenia management. 
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These results are consistent with those from the overall NeuCuP analysis, which included 
patients ≥18 years of age. In that analysis (descriptive analysis of unmodelled data), 5% of 
patients in the PP pegfilgrastim group and 16% in the CP neutropenia management group 
experienced FN, with 3% and 10%, respectively, experiencing FN in cycle 1 [21]. Another 
recent study in elderly breast cancer patients evaluated the use of pegfilgrastim as primary or 
secondary prophylaxis to support the adjuvant dose-intense regimen FEC100, with results 
largely reflecting the findings of the present analysis [25]. While overall neutropenic events 
(which encompassed grade 4 neutropenia, neutropenia with fever and infectious 
complications) did not differ between the different approaches to prophylaxis (PP, 80%; 
secondary prophylaxis, 72%), FN-related hospitalization (0% vs. 17%) and actual FN 
reported as a serious adverse event (7% vs. 27%) were less frequent in the PP group. 
Moreover, a greater proportion of patients receiving pegfilgrastim PP received their 
chemotherapy cycles at planned dose on schedule (87%) than those receiving secondary 
prophylaxis (69%). 
 
Apart from the relative difference in FN occurrence between the PP and CP cohorts, the 
absolute incidence of FN in elderly patients is of interest. It was higher in the CP cohort of the 
present analysis (24% overall and 15% in cycle 1) than in that of the overall NeuCuP study. 
This was perhaps expected, as elderly patients have previously been reported to be at 
increased risk of chemotherapy-related haemotoxicity compared with younger patients [13–
15]. For example, in a multivariate analysis of 6642 patients receiving adjuvant chemotherapy 
for breast cancer, older patients were significantly more likely to have grade 4 haematological 
toxicity, to discontinue treatment for toxicity, or to die of acute myeloid leukaemia or 
myelodysplastic syndrome [13]. This increased toxicity of chemotherapy in elderly patients 
may be related to a number of factors. Modified drug metabolism in the elderly may not be 
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taken into account in the dosing of drugs [26,27], and there may also be reduced bone marrow 
function and depleted reserves of haematopoietic stem cells [17]. The impact of age on risk of 
haemotoxicity, however, remains controversial. A recent study in 976 patients aged ≥70 years 
showed no increase in the risk of haematological toxicity with old age per se [28]. It seems 
likely, therefore, that the actual risk of toxicity also depends on the patient population, pre-
treatment with systemic therapies, comorbidities and other factors (many of which may be 
more common in elderly patients). For example, risk of haematological toxicity is also 
thought to increase with increasing disease stage [6,9].  
 
Elderly breast cancer patients often receive ‘less toxic’ chemotherapy (e.g. anthracycline-free 
regimens such as CMF), and the planned and delivered intensity of chemotherapy may be 
lower than in younger patients [19,29–31]. There is, however, increasing evidence that elderly 
patients can tolerate standard chemotherapies, provided that they receive appropriate support. 
In the present analysis, all patients were receiving taxane-based regimens, which are 
associated with a high risk of myelosuppression [6]. In another pooled analysis involving 
1067 elderly patients receiving taxane-based chemotherapy, neutropenia grade III–IV 
occurred in 57.4% of patients, with febrile neutropenia in 6.92%, anaemia in 3.3% and 
thrombopenia in 5.0%, which are similar to the incidences reported in younger patients [32]. 
Thus, elderly patients can tolerate taxanes with G-CSF support. Where clinically appropriate, 
such treatment should not be withheld.  
 
The present analysis also highlights the low usage of G-CSF primary prophylaxis in the CP 
neutropenia management of elderly patients. As in the overall study population, G-CSF use 
varied widely, with around 60–70% of patients in any given cycle receiving no G-CSF. Of 
those that did receive G-CSF and for whom the type of G-CSF was specified, pegfilgrastim 
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was generally more common than daily G-CSF, particularly in the later cycles. This variation 
in G-CSF use, particularly the low incidence of G-CSF prophylaxis, is typical and reflects the 
use of G-CSF in routine practice. This was demonstrated in a recent prospective study in 
community practice in the USA, in which 42% of patients were being treated for breast 
cancer, 24% had lung cancer, 14% colorectal cancer, 12% lymphoma (non-Hodgkin’s 
lymphoma, 10%; Hodgkin’s disease, 2%) and 8% ovarian cancer [33]. Anthracyclines, 
platinum-based agents and taxanes were administered to 40%, 31% and 30% of patients, 
respectively, with 80% of patients receiving 2 or more concomitant agents. Nevertheless, the 
overall rate of G-CSF primary prophylaxis was only 18%. In patients with Stage I–III breast 
cancer receiving a planned RDI ≥85% and G-CSF primary prophylaxis, the incidence of 
febrile or severe neutropenia in Cycles 1–3 was 21.3% (FN, 10.9%) compared with 53.6% 
(FN, 19.4%) in those not receiving primary prophylaxis [33]. 
 
Both reduction in FN risk and facilitation of chemotherapy delivery have the potential to 
translate into survival benefits. For example, a recent meta-analysis from Kuderer et al. 
demonstrates that G-CSF primary prophylaxis is associated with significantly less early and 
infection-related mortality in cancer patients compared with placebo or no treatment [2]. 
Improved survival has also been demonstrated in breast cancer patients who receive full 
planned rather than suboptimal doses of adjuvant chemotherapy (e.g. RDI ≥85% vs < 85%) 
[3–5]. In the present study, fewer patients receiving pegfilgrastim PP required chemotherapy 
dose reductions. The majority of our patient population had early stage disease, but around a 
third had metastases. The benefit of delivering full RDI to late-stage patients is less clear; it 
could lead to prolonged life [7], but this must be balanced against toxicity to the patient. 
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Data from the current analysis represent a useful contribution to the literature concerning 
management of malignancies in elderly patients. The inclusion of 254 elderly patients 
represents a sizeable cohort for this relatively understudied patient population, but the sample 
size was not large enough to justify statistical modelling of data as performed for the complete 
dataset. All analyses are therefore descriptive and must be viewed in that context. Further 
studies focussing on cancer management in the elderly would be beneficial. For example, with 
reference to the current study, the effects of pegfilgrastim PP and CP neutropenia 
management on outcomes and survival in elderly patients remain to be explored.  
 
The trials included in this analysis are of varying design, while some arms from RCTs were 
excluded from the CP group due to protocol driven use of G-CSF preventing their 
classification as ‘current practice’. These features can be viewed as a limitation in comparison 
with a traditional meta-analysis, but the inclusion of observational and retrospective data from 
different studies is a potential strength since they provide a better approximation of current 
practice than could be achieved in a randomized trial. Comparison of the available baseline 
demographic and disease characteristics of the two groups showed that the two groups were 
likely to be well balanced, but it should be noted that some data were lacking (e.g. in relation 
to performance status). Lastly, our analysis does not address the tolerability of the two 
different approaches to neutropenia management, however, previous authors have shown 
pegfilgrastim primary prophylaxis to be as well tolerated as daily G-CSF [34, 35]. 
 
In conclusion, these descriptive analyses in elderly breast cancer patients receiving 
chemotherapy with a moderately high to high FN risk, suggest that PP pegfilgrastim is 
associated with a lower overall incidence of FN compared with CP neutropenia management. 
PP pegfilgrastim also resulted in fewer dose reductions. Thus, these results, which are in 
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agreement with evidence-based guidelines and other recent data, show that pegfilgrastim 
provided effective PP in elderly patients, who are particularly vulnerable to FN and its 
complications, potentially increasing the possibility of treatment with curative intent in this 
patient population. CP neutropenia management may not provide adequate protection against 
FN in elderly patients, which could place them at risk of increased morbidity and mortality. 
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Table 1. Studies included in the NeuCuP breast cancer sub group analysis of elderly patients 
Author Reference Study Regimen Disease stage PP pegfilgrastim CP 
Vogela J Clin Oncol 2005;23:1178–84 RCT Doc I–IV n=54 n=45 
(Secondary pegfilgrastim 
prophylaxis allowed) 
Holmesa J Clin Oncol 2002;20:727–31 RCT ADoc II–IV n=10  
Holmesa Ann Oncol 2002;13:903–9 RCT ADoc II–IV n=5  
Greena Ann Oncol 2003;14:29–25 RCT ADoc II–IV n=5  
Balduccib Oncologist 2007;12:1416–24 RCT Various I–IV n=22  
Von 
Minckwitzc 
Ann Oncol 2008;19:292–8 RCT (selected 
cohorts) 
DocAC I–III n=31 n=26 
(Primary ciprofloxacin 
prophylaxis. 
G-CSF not precluded) 
Ozera Oncologist 2007;12:484–94 Prosp Open-label Various I–IV n=16  
Kaufmana Breast Cancer Res Treat 2004;88(Suppl 1): 
#1054 
RCT Various II–IV n=7  
Lopez Pousab Ann Oncol 2006;19(Suppl 9):#1028P Prosp Obs Various I–IV  n=8 
(Any/no G-CSF) 
Pettengelld Support Care Cancer 2008;16:1299–309 Prosp Obs Various I–III  n=6 
(Any/no G-CSF) 
Morrisonb J Manag Care Pharm 2007;13:337–48 Retrosp Various I–IV  n=19 
(Any/no G-CSF) 
*Patients aged ≥65 years 
A, doxorubicin; C, cyclophosphamide; CP, current practice neutropenia management; Doc, docetaxel; G-CSF, granulocyte colony stimulating factor; Obs, 
observational (i.e. non-interventional) study; PPP, primary prophylaxis; Prosp, prospective (interventional) trial; RCT, randomised clinical trial; Retrosp, 
retrospective 
Definition of febrile neutropenia: aabsolute neutrophil count (ANC) <0.5 × 109/L and temperature ≥38.2 ºC; bANC <1.0 × 109/L and temperature ≥38.0 ºC; 
cANC <1.0 × 109/L and three oral temperature measurements >38.0 ºC or a single measurement >38.5 ºC; dANC <0.5 × 109/L and temperature ≥38.0 ºC. 
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Table 2. Baseline demographics, disease characteristics and chemotherapy regimens received 
on study 
 PP pegfilgrastim 
(n = 150) 
Current practice 
(n = 104) 
Age (mean ± SD), years 69.2 ± 4.0 68.2 ± 3.1 
Sex, n (%) 
 Female 
 Male  
 
149 (99) 
1 (1) 
 
103 (99) 
1 (1) 
ECOG status, n (%) 
 0–1 
 ≥2 
 Unknown 
 
142 (95) 
6 (4) 
2 (1) 
 
82 (79) 
6 (6) 
16 (15) 
Disease stage, n (%) 
 I–III 
 IV 
 Unknown 
 
95 (63) 
55 (37) 
0 
 
63 (61) 
32 (31) 
9 (9) 
Prior therapy, n (%) 
 None 
 Chemotherapy only 
 Radiotherapy only 
 Both 
 Unknown 
 
97 (65) 
22 (15) 
5 (3) 
21 (14) 
5 (3) 
 
65 (63) 
17 (16) 
2 (2) 
12 (12) 
8 (8) 
Oestrogen receptor status, n (%) 
 Negative 
 Positive 
 Unknown 
 
48 (32) 
53 (35) 
49 (33) 
 
18 (17) 
34 (33) 
52 (50) 
Chemotherapy regimen, n (%) 
 Doc 
 DocAC 
 ADoc 
 AC-Doc 
 EDoc 
 AT 
 EC-Doc 
 
61 (41) 
36 (24) 
42 (28) 
7 (5) 
2 (1) 
2 (1) 
0 
 
49 (47) 
28 (27) 
7 (7) 
10 (10) 
5 (5) 
2 (2) 
3 (3) 
Patients starting each 
chemotherapy cycle, n (%) 
 2 
 3 
 4 
 5 
 6 
 
 
148 (99) 
141 (94) 
135 (90) 
40 (27) 
37 (25) 
 
 
102 (98) 
97 (93) 
87 (84) 
42 (40) 
39 (38) 
A, doxorubicin; C, cyclophosphamide; Doc, docetaxel; E, epirubicin; ECOG, Eastern Cooperative 
Oncology Group; T, paclitaxel 
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Table 3. Haematological toxicities occurring in elderly patients 
Maximum grade PP pegfilgrastim (n=150) Current practice (n=104) 
 
n (%) 95% CI* n (%) 95% CI* 
Neutropenia 
 Grade 2 
 Grade 3 
 Grade 4 
 
5 (3) 
11 (7) 
54 (36) 
 
0, 7 
3, 12 
28, 44 
 
3 (3) 
15 (14) 
60 (58) 
 
0, 7 
7, 22 
48, 68 
Leukopenia 
 Grade 2 
 Grade 3 
 Grade 4 
 
7 (5) 
32 (21) 
42 (28) 
 
1, 8 
14, 28 
20, 36 
 
8 (8) 
42 (40) 
28 (27) 
 
2, 13 
30, 50 
18, 36 
Anaemia, n 
 Grade 2 
 Grade 3 
 Grade 4 
 
48 (32) 
4 (3) 
0 
 
24, 40 
0, 6 
– 
 
37 (36) 
3 (3) 
0 
 
26, 45 
0, 7 
– 
Thrombocytopenia, n 
 Grade 2 
 Grade 3 
 Grade 4 
 
25 (17) 
7 (5) 
1 (1) 
 
10, 23 
1, 8 
0, 2 
 
5 (5) 
4 (4) 
5 (5) 
 
0, 9 
0, 8 
0, 9 
*95% CI for proportion of patients with toxicity of maximum grade specified at any time 
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Figure titles and legends 
 
Figure 1. G-CSF use by elderly patients in the CP cohort in each cycle 
 
*Daily G-CSF and filgrastim 
 
Figure 2. Incidence of FN (± 95% CI) in elderly patients 
 
CP, current practice neutropenia management; PP, pegfilgrastim primary prophylaxis 
 
Figure 3. Incidence of FN-related hospitalisation (± 95% CI) in elderly patients 
 
CP, current practice neutropenia management; PP, pegfilgrastim primary prophylaxis 
 
Figure 4. Incidence of dose delays >3 days and >7 days (± 95% CI) in elderly patients in one 
or more of cycles 1–6 
 
CP, current practice neutropenia management; PP, pegfilgrastim primary prophylaxis 
 
Figure 5. Incidence of dose reductions ≥10% and ≥15% (± 95% CI) in elderly patients in one 
or more of cycles 1–6 
 
CP, current practice neutropenia management; PP, pegfilgrastim primary prophylaxis 
 
 
73%
69% 70%
71%
55%
62%
8%
7%
6%
13%
18% 16%
16%
26% 18%
6% 7% 7%
11%
17%
21%
1%
2%
1%
0%
20%
40%
60%
80%
100%
1 (n=104) 2 (n=102) 3 (n=97) 4 (n=87) 5 (n=42) 6 (n=39)
Cycle
P
a
t
i
e
n
t
s
 
(
%
)
Combination*
Unspecified
Pegfilgrastim only
Daily G-CSF only
No G-CSF
*Daily G-CSF and filgrastim
Figure 1
6%
24%
3%
15%
0
5
10
15
20
25
30
35
PP (n=150) CP (n=104) PP (n=150) CP (n=104)
FN (all cycles) FN (cycle 1)
P
a
t
i
e
n
t
s
 
(
%
)
CP, current practice neutropenia management; PP, pegfilgrastim primary prophylaxis
Figure 2
4%
5%
13%15%
0
5
10
15
20
25
PP (n=150) CP (n=104) PP (n=150) CP (n=104)
Hospitalisation for FN (all cycles) Hospitalisation for FN (cycle 1)
P
a
t
i
e
n
t
s
 
(
%
)
CP, current practice neutropenia management; PP, pegfilgrastim primary prophylaxis
Figure 3
6%5%
21%14%
0
5
10
15
20
25
30
35
PP (n=150) CP (n=104) PP (n=150) CP (n=104)
P
a
t
i
e
n
t
s
 
(
%
)
Dose delay > 3 days Dose delay >7 days
CP, current practice neutropenia management; PP, pegfilgrastim primary 
Figure 4
29%15%15% 32%
0
5
10
15
20
25
30
35
40
45
PP (n=150) CP (n=104) PP (n=150) CP (n=104)
P
a
t
i
e
n
t
s
 
(
%
)
CP, current practice neutropenia management; PP, pegfilgrastim primary prophylaxis
15% dose reduction10% dose reduction
Figure 5
